Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma

Oral Oncology

Volumn 40, Issue 10, 2004, Pages 1000-1006

  Kurita, Hiroshi ^a   Yamamoto, Etsuhide ^b   Nozaki, Shinichi ^b   Wada, Shigehito ^c   Furuta, Isao ^c   Kurashina, Kenji ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Combined chemotherapy; Docetaxel; Dose level; Nedaplatin; Neoadjuvant chemotherapy; Oral cancer; Preoperative; Squamous cell carcinoma; Toxicity

Indexed keywords

DOCETAXEL; NEDAPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MOUTH CARCINOMA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOUTH NEOPLASMS; ORGANOPLATINUM COMPOUNDS; REMISSION INDUCTION; TAXOIDS; TREATMENT OUTCOME;

EID: 7044230901     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2004.05.002     Document Type: Article

References (28)

1. L.B. Harris R.B. Sessions W.K. Hong Head and neck cancer: a multidisciplinary approach 1998 Lippincott-Raven Philadelphia
2. D. Franceschi, R. Gupta, and R.H. Spiro Improved survival in the treatment of squamous carcinoma of the oral tongue Am. J. Surg. 166 1993 360 365
3. J. Verwij, P.C. de Jong, and M. de Mulder Induction chemotherapy with cisplatin and continuous infusion 5-fluorouracil in locally far-advanced head and neck cancer Am. J. Clin. Oncol. 12 1989 420 424
4. J.J. Mazeron, M. Martin, and B. Brun Induction chemotherapy in head and neck cancer: results of a phase III trial Head Neck 14 1992 85 91
5. K. Al-Kourainy, J. Kish, and J. Ensley Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer Cancer 59 1987 233 238
6. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program Cancer 60 1987 301 311
7. J. Ensley, J. Crissman, and J. Kish The impact of conventional morphologic analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin-containing combination chemotherapy Cancer 57 1986 711 717
8. J.P. Pingnon, J. Bourhis, C. Domenge, L. Designè, and MACH-NC Collaborative Group Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data Lancet 355 2000 949 955
9. Y. Sasaki, T. Shinkai, and K. Eguchi Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay Cancer Chemother. Pharmacol. 27 1991 263 270
10. D.S. Alberts, P.T. Fanta, and K.L. Ruuing In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers Cancer Chemother. Pharmacol. 39 1997 493 497
11. M. Tsukuda, T. Yoshida, and A. Kubota Experimental study on the anti-tumor effects of CDDP derivatives against the head and neck squamous cell carcinoma cell lines Gan To Kagaku Ryoho 15 1988 2811 2814 [Japanese literature]
12. Y. Inuyama, H. Miyake, M. Horiuchi, K. Hayasaki, S. Komiyama, and K. Ota A late phase II clinical study of cis-diamine glyrolato platinum, 254-S, for head and neck cancers Gan To Kagaku Ryoho 19 1992 871 877
13. A.I. Dreyfuss, J.R. Clark, and C.M. Norris Docetaxel: an active drug for squamous cell carcinoma of the head and neck J. Clin. Oncol. 14 1996 1672 1678
14. G. Catimel, J. Verweij, and V. Mattijssen Docetaxel (Taxotere): an active drug for treatment of patients with advanced squamous cell carcinoma of the head and neck Ann. Oncol. 5 1994 533 537
15. S. Ebihara, H. Fujii, and Y. Sasaki A late phase II study of docetaxel (Taxotere) in patients with head and neck cancer (HNC) Proc. Am. Soc. Clin. Oncol. 399a 1997 [Abstr 1425]
16. C. Couteau, S. Leyvraz, and D. Outlid-Aissa A phase II study of docetaxel in squamous cell carcinoma (SCC) of the head and neck Proc. Am. Soc. Clin. Oncol. 15 1996 315 [Abst 889]
17. P. Schöffski, G. Catimel, and Q.S.T. Planting Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck Ann. Oncol. 10 1999 119 122
18. A. Forastiere, B. Glisson, and B. Murphy A phase II study of docetaxel and cisplatin in patients with locally advanced, recurrent, and/or metastatic squamous cell carcinoma of the head and neck (SCCHN), not curable by standard therapy Proc. Am. Soc. Clin. Oncol. 17 1998 399a [Abstr 1540]
19. H. Yamada, N. Uchida, R. Maekawa, and T. Yoshioka Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel Cancer Lett. 172 2001 17 25
20. L.H. Sobin C.H. Wittenkind TNM classification of malignant tumors 5th ed. 1997 John Wiley & Sons, Inc. New York
21. World Health Organization Handbook for reporting results of cancer treatment WHO Offset Publication No. 48 1979 World Health Organization Geneva, Switzerland
22. Y. Shimosato, S. Oboshi, and K. Baba Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas Jpn. J. Clin. Oncol. 1 1971 19 35
23. Veterans Affairs Laryngeal Cancer Study Group V Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer N. Engl. J. Med. 324 1991 1685 1689
24. J. Kish, J. Ensley, and J. Jacobs A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck Cancer 56 1985 2740 2744
25. J. Lefebvre, D. Chevalier, and B. Luboinske Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial J. Natl. Cancer Inst. 1996 890 898
26. A. Paccagnella, A. Orlando, and C. Marchoiori Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del collo J. Natl. Cancer Inst. 86 1994 265 272
27. E. Vokes, R. Wechselbaum, and R. Mick Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer J. Natl. Cancer Inst. 84 1992 877 882
28. R. Haddad, R.B. Tishler, and C.M. Norris Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment The Oncologist 8 2003 35 44